Literature DB >> 11077328

Analysis of 154 actual five-year survivors of gastric cancer.

S N Hochwald1, S Kim, D S Klimstra, M F Brennan, M S Karpeh.   

Abstract

Gastric cancer patients in the United States have a poor prognosis with a collective 5-year survival rate of less than 15%. We identified a subset of actual 5-year survivors (long-term survivors) and analyzed clinicopathologic variables predictive of recurrence and survival beyond the 5-year mark. A review of our prospective database from July 1985 to February 1993 revealed 154 patients who were long-term survivors and 280 patients who died of disease prior to 5 years (short-term survivors) following curative resection (R0). Tumor (T) stage, nodal (N) status, tumor location, and median number of positive nodes were compared between the two groups. Univariate and multivariate analysis of disease-free and greater than 5-year disease-specific survival was performed within the long-term survivors. Among the long-term survivors, 29% were classified as "early gastric cancers" (T1NX). The median number of positive nodes (0 vs. 5; P <0.001) and percentage of lesions that were T1/T2 (60% vs. 19%; P <0.001), node negative (58% vs. 15%; P <0.001), or proximal (40% vs. 65%; P <0.001) was significantly different in long-term survivors vs. short-term survivors, respectively. Of the 154 five-year survivors, gastric cancer recurred in 23, and 13 patients (8%) died of the disease at a median of 84 months from the original diagnosis. On univariate and multivariate analysis of prognostic factors in the long-term survivors, only the Lauren histologic classification predicted disease-specific and disease-free survival with diffuse histologic types faring significantly less well. T stage and N status are powerful prognostic factors of outcome within the first 5 years after curative resection of gastric carcinoma. However, the Lauren histologic type emerges as the dominant predictor of outcome once a patient with gastric cancer has survived for 5 years or more.

Entities:  

Mesh:

Year:  2000        PMID: 11077328     DOI: 10.1016/s1091-255x(00)80095-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 2.  Radical surgery for gastric cancer. A review of the Japanese experience.

Authors:  Y Noguchi; T Imada; A Matsumoto; D G Coit; M F Brennan
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

3.  Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group.

Authors:  J D Roder; K Böttcher; R Busch; C Wittekind; P Hermanek; J R Siewert
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

4.  Progress in gastric cancer surgery in Japan and its limits of radicality.

Authors:  K Maruyama; K Okabayashi; T Kinoshita
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

5.  Prognostic significance of the number of positive lymph nodes in gastric carcinoma.

Authors:  Y Adachi; T Kamakura; M Mori; H Baba; Y Maehara; K Sugimachi
Journal:  Br J Surg       Date:  1994-03       Impact factor: 6.939

6.  The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification.

Authors:  Y Kodera; Y Yamamura; Y Shimizu; A Torii; T Hirai; K Yasui; T Morimoto; T Kato; T Kito
Journal:  J Am Coll Surg       Date:  1998-12       Impact factor: 6.113

7.  Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer.

Authors:  T Ichikura; S Tomimatsu; Y Okusa; K Uefuji; S Tamakuma
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

8.  The prognostic value of Laurén's histopathological classification system and ABO blood groups in patients with stomach carcinoma.

Authors:  A Viste; G E Eide; K Halvorsen; H Maartmann-Moe; O Søreide
Journal:  Eur J Surg Oncol       Date:  1986-06       Impact factor: 4.424

Review 9.  Prognostic factors for gastric cancer influencing clinical practice.

Authors:  J D Harrison; J W Fielding
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

10.  Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma.

Authors:  M M Ribeiro; J A Sarmento; M A Sobrinho Simões; J Bastos
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

View more
  21 in total

1.  Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence.

Authors:  Jingyu Deng; Han Liang; Dan Sun; Rupeng Zhang; Hongjie Zhan; Xiaona Wang
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

2.  Investigation of the recurrence patterns of gastric cancer following a curative resection.

Authors:  Jingyu Deng; Han Liang; Dianchang Wang; Dan Sun; Yi Pan; Yong Liu
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

3.  Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?

Authors:  Markus Menges
Journal:  World J Gastrointest Oncol       Date:  2011-01-15

Review 4.  MiRNA as potential biomarkers and therapeutic targets for gastric cancer.

Authors:  Vivian Yvonne Shin; Kent-Man Chu
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression.

Authors:  Solbi Kim; Ji-Eun Kim; Nayoung Kim; Mina Joo; Myung-Won Lee; Heung Jin Jeon; Hyewon Ryu; Ik-Chan Song; Gyu-Yong Song; Hyo Jin Lee
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

6.  Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

Authors:  Mohammad Mobayed; Lance K Heilbrun; Anthony F Shields; Tara Washington; Raghu Venkatramanamoorthy; Philip A Philip; Bassel F El-Rayes
Journal:  Case Rep Oncol       Date:  2009-11-21

Review 7.  Clinical significance of lymph node metastasis in gastric cancer.

Authors:  Jing-Yu Deng; Han Liang
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 8.  Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction.

Authors:  Markus Menges; Thomas Hoehler
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-04       Impact factor: 4.553

Review 9.  Emerging molecular basis of hematogenous metastasis in gastric cancer.

Authors:  Jing Zhong; Yan Chen; Liang-Jing Wang
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 10.  Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.

Authors:  Simon Pernot; Thibault Voron; Geraldine Perkins; Christine Lagorce-Pages; Anne Berger; Julien Taieb
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.